Baylor inks anti-cancer vax development pact

Japan-based SBI Biotech and Baylor Research Institute have inked a licensing deal and development agreement to develop anti-cancer vaccines for Asian markets, which could possibly include Japan, Taiwan and Korea.

The licensing agreement allows SBI to conduct clinical trials on early-stage cancer patients using Baylor's "dentritic cell immunotherapy"--a treatment designed to work in conjunction with others, such as radiation and chemotherapy. Over the past five years, the Dallas-based institute's clinical trials have only included about 100 cancer patients, all of whom have had late-stage cancer and declining immune systems.

Under the terms of the agreement, SBI will pay Baylor about $3 million in acceleration fees and another $3 million in SBI stock, with potential milestone and royalty fees that could reach a half-million.

- check out the Dallas Business Journal for more

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.